A Study of Fisetin to Treat Carpal Tunnel Syndrome

NCT ID: NCT05416515

Last Updated: 2025-12-24

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 40 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-10-09
• Study Completion Date: 2025-01-24

Brief Summary

This research study is being conducted to investigate the safety and effectiveness of the drug Fisetin for mild or moderate carpal tunnel syndrome (CTS).

Detailed Description

FITCATS trial will enroll approximately 40 subjects with mild-moderate CTS and evidence of senescence from blood markers into a short term (180 days) prospective phase 2 study of Fisetin therapy, using as outcome measures a well-accepted patient reported outcome questionnaire (Boston CTS questionnaire, BCTQ) as well as reduction from baseline in senescence markers in the blood, including SASP factors and inflammatory markers. Based on the known performance of the BCTQ, the investigators estimate that a sample size of 40 will be sufficient to show a clinically important difference in outcome, if it is present. Each subject will be enrolled for a six-month period. Subjects may withdraw at any time, for any reason.

Conditions

Carpal Tunnel Syndrome

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Carpal Tunnel Syndrome

Adult men and women who have a clinical diagnosis for Carpal Tunnel Syndrome (CTS) will receive Fisetin for 2 day periods for 2 months

Group Type: EXPERIMENTAL

Fisetin

Intervention Type: DRUG

100 mg capsules orally for 2 consecutive days and, after 1 month, another 2 consecutive days

Interventions

Fisetin

100 mg capsules orally for 2 consecutive days and, after 1 month, another 2 consecutive days

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Males and females between age 21 and 80 years of age.
• Symptoms of numbness or tingling for at least 4 weeks in at least two digits on one hand that include thumb, index, long, or radial border of ring finger.
• Classic or probable carpal tunnel syndrome on Katz-Stirrat hand diagram.
• A clinical diagnosis of carpal tunnel syndrome. Patients with bilateral CTS will have the more severe hand enrolled.
• Able to complete English-language questionnaires and clinical evaluations.
• Willingness to avoid pregnancy.

• Female participants of childbearing potential must have a negative pregnancy test at screening (serum) and before the first dose on Day 1 (urine), before the third dose on Day 29 (urine), and 60 days after the final dose on day 60 (urine).
• Sexually active female participants of childbearing potential must agree to take appropriate precautions to avoid pregnancy from screening until 30 days after the last dose of study drug (day 60). Permitted methods in preventing pregnancy (see Appendix A) will be communicated to the participants and their compliance confirmed.
• All female participants of childbearing potential will refrain from donating oocytes from screening-day 60 of the study.
• Women without child bearing potential (ie., surgically sterile with hysterectomy and/or bilateral oophorectomy and/or bilateral salpingectomy OR ≥ 12 months of amenorrhea and at least 50 years of age) are eligible to participate without the above precautions.
• Willing and able to comply with study procedures and requirements and attend all study visits as defined in this protocol.

Exclusion Criteria

• Unable or unwilling to give informed consent.
• Pregnant or breast feeding
• Previous carpal tunnel release on the study hand
• History of steroid injection into carpal tunnel or surgery on the affected wrist within the past 6 months.
• Prisoners, institutionalized individuals, or others who may be considered vulnerable populations, such as individuals with dementia.

The following laboratory tests as indicated or as per clinical judgement:

• Bilirubin > 2.0; serum aspartate transaminase (AST) > 4 X upper limit of normal, or alanine aminotransferase (ALT) > 4 X upper limit of normal as a marker of liver disease
• Hemoglobin < 7g/dL; white blood cell count ≤2,000/mm3 (≤2.0 x 109/L) or ≥20,000/mm3 (≥20 x 109/L); platelet count ≤40,000/μL (≤40 x 109/L); absolute neutrophil count ≤1 x 109/L; lymphocyte count <0.3 x 109/L at screening as a marker of poor nutrition
• Plasma and/or serum fasting glucose > 300 or HbA1c > 9 as a marker of poor diabetic control
• Creatinine >2.5, cystatin c >3 or eGFR< 25 ml/min/1.73 m2 as a marker of advanced kidney disease,
• CRP > 10 or ESR >25 as a marker of systemic inflammation
• Unstable (as per clinical judgement) major cardiovascular, renal, endocrine, immunological, or hepatic disorder

• History of diverticulitis or diverticulosis with GI bleeding, as per clinical judgement
• Human immunodeficiency virus infection
• Known active hepatitis B or C infection
• Invasive fungal infection
• Uncontrolled (as per clinical judgement) pleural/pericardial effusions or ascites
• New/active invasive cancer except non-melanoma skin cancers

• Known hypersensitivity or allergy to Fisetin or other flavonoids
• Currently participating in another study using Fisetin or currently taking any flavonoid as a nutritional supplement. Note that consuming foods rich in flavonoids is NOT an exclusion, both because flavonoids are present in almost all fruits and vegetables, making such an exclusion impossible as a practical matter, and, from a scientific perspective, the amount of flavonoids in general, and Fisetin in particular, present in foods is far lower than the dose that will be administered in the trial.
• Patients currently taking medications listed in the Investigator Brochure are excluded unless medication can be safely held following the guidelines in the Investigator Brochure.
• If the patient is required to initiate any medication listed in the Investigator Brochure during the study, the PI will reassess their continued participation in the study.

• Minimum Eligible Age: 21 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Peter C. Amadio, M.D.

OTHER

Sponsor Role: lead

Responsible Party

Peter C. Amadio, M.D.

Principal Investigator

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Peter C Amadio, MD

Role: PRINCIPAL_INVESTIGATOR

Mayo Clinic

Locations

Mayo Clinic in Rochester

Rochester, Minnesota, United States

Countries

United States

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

21-010406

Identifier Type: -

Identifier Source: org_study_id